Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24612581 | 1.00 | CTSL (0.55) | CTSLGAAMEN1RAB9AKMT2A | |
| SCHEMBL6811621 | 0.89 | L3MBTL1 (0.57) | GAAMEN1RAB9AKMT2ANPSR1 | |
| SCHEMBL6811627 | 0.89 | L3MBTL1 (0.57) | GAAMEN1RAB9AKMT2ANPSR1 | |
| SCHEMBL25917199 | 0.88 | METTL3 (0.52) | CTSLGAAMAPK1NPSR1TDP1 | |
| SCHEMBL27649749 | 0.87 | GAA (0.60) | CTSLGAAMAPK1NPSR1TDP1 | |
| SCHEMBL25917253 | 0.87 | CTSK (0.53) | CTSLGAAKMT2AMAPK1NPSR1 | |
| SCHEMBL25408895 | 0.81 | CTSL (0.66) | CTSLGAAKMT2AATMMETTL3 | |
| SCHEMBL9134153 | 0.79 | CTSL (0.64) | CTSLGAAMEN1KMT2AMAPK1 | |
| SCHEMBL5148495 | 0.79 | CTSL (0.61) | CTSLGAAATMMETTL3CTSB | |
| SCHEMBL941250 | 0.79 | CTSL (0.61) | CTSLGAAATMMETTL3CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372307-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4213840-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | Albert Einstein College of Medicine (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022061174-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372307-A1 | COMBINATION THERAPY USING BAX ACTIVATOR AGENT | BAK1, BCL2L1, BCL2A1 | CTSL 472/4885GAA 2234/4885MEN1 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.